Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barré syndrome

Journal of Neuroscience Research

Volumn 88, Issue 8, 2010, Pages 1651-1663

  Usuki, S ^a   Taguchi, K ^b   Thompson, S A ^a   Chapman, P B ^c   Yu, Robert K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anti idiotype antibody; Campylobacter jejuni; Ganglioside; GD3 ganglioside; Guillain Barr ; Lipooligosaccharide; Syndrome

Indexed keywords

GANGLIOSIDE ANTIBODY; IDIOTYPIC ANTIBODY; LIPOOLIGOSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BEC2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE NEURITIS; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PURIFICATION; FEMALE; GUILLAIN BARRE SYNDROME; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; ISOLATION PROCEDURE; MAXIMUM PLASMA CONCENTRATION; MORPHOLOGY; MOTONEURON; MOTOR NERVE; NERVE FIBER; NERVE FUNCTION; NEURITIS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACTION POTENTIALS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; BIOTINYLATION; CAMPYLOBACTER JEJUNI; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FREUND'S ADJUVANT; GANGLIOSIDES; LIPOPOLYSACCHARIDES; MOTOR NEURONS; MUSCLE, SKELETAL; NERVE TISSUE PROTEINS; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION DISEASES; ORGAN CULTURE TECHNIQUES; RATS; ROTAROD PERFORMANCE TEST; SCIATIC NERVE; SPINAL CORD; TIME FACTORS;

EID: 77952359297     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22330     Document Type: Article

References (48)

1. Andersen H, Nielsen JF, Nielsen VK. 1994. Inability of insulin to maintain normal nerve function during high-frequency stimulation in diabetic rat tail nerves. Muscle Nerve 17:80-84. (Pubitemid 24012106)
2. Ariga T, Yu RK. 2005. Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: review of clinical features and antibody specificities. J Neurosci Res 80:1-17. (Pubitemid 40577288)
3. Barrett JS, Fisher SJ, Wahl RL. 1997. Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies. Cancer Immunol Immunother 44:173-178.
4. Birren JE, Wall PD. 1956. Age changes in conduction velocity, refractory period, number of fibers, connective tissue space and blood vessels in sciatic nerve of rats. J Comp Neurol 104:1-16.
5. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. 2002. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 51:673-680. (Pubitemid 34568844)
6. Buchwald B, Zhang G, Vogt-Eisele AK, Zhang W, Ahangari R, Griffin JW, Hatt H, Toyka KV, Sheikh KA. 2007. Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis 28:113-121. (Pubitemid 47432904)
7. Caporale CM, Papola F, Fioroni MA, Aureli A, Giovannini A, Notturno F, Adorno D, Caporale V, Uncini A. 2006. Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 177:112-118. (Pubitemid 44108242)
8. Chapman PB. 2003. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Invest Drugs 4:710-715.
9. Chapman PB, Houghton AN. 1991. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 88:186-192.
10. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. 2004. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717-4723. (Pubitemid 38955522)
11. Dalakas MC. 2004a. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367-2375. (Pubitemid 38656304)
12. Dalakas MC. 2004b. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102:177-193.
13. Dunham NW, Miya TS. 1957. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc 46:208-209.
14. Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. 2004. Functional polymorphisms in LPS recepters CD14 and TLR4 are not assiciated with dieseas susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol 150:132-138. (Pubitemid 38481656)
15. Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, Laman JD, van Doorn PA. 2005. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 64:44-49. (Pubitemid 40082935)
16. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
17. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ. 1999. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104:697-708. (Pubitemid 29536355)
18. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV. 2001. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56:758-765. (Pubitemid 32240096)
19. Hughes RA, Hadden RD, Gregson NA, Smith KJ. 1999. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 100:74-97.
20. Jones BJ, Roberts DJ. 1968. The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J Pharm Pharmacol 20:302-304.
21. Kaida T, Ariga T, Yu RK. 2009. Antiglycolipid antibodies and their pathopysiological effects on Guillain-Barré syndrome and related diseases: a review. Glycobiology 19:676-692.
22. Kieseier BC, Meyer Zu Horste G, Lehmann HC, Gold R, Hartung HP. 2008. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 21:555-562.
23. Koga M, Yuki N, Ariga T, Hirata K. 1999. Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: their association with cranial nerve dysfunction. J Neurol Sci 164:50-55. (Pubitemid 29256073)
24. Kuwabara S. 2004. Guillain-Barré syndrome: epidemiology, pathophysiology and management. Drugs 64:597-610.
25. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. 1984. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119:841-879.
26. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. 1992. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 59:1844-1849.
27. Ribeiro-Resende VT, Oliveira-Silva A, Ouverney-Brandao S, Santiago MF, Hedin-Pereira C, Mendez-Otero R. 2007. Ganglioside 9-O-acetyl GD3 expression is upregulated in the regenerating peripheral nerve. Neuroscience 147:97-105. (Pubitemid 46873846)
28. Rinaldi S, Willison HJ. 2008. Ganglioside antibodies and neuropathies. Curr Opin Neurol 21:540-546.
29. Sivadon-Tardy V, Orlikowski D, Rozenberg F, Caudie C, Sharshar T, Lebon P, Annane D, Raphael JC, Porcher R, Gaillard JL. 2006. Guillain-Barré syndrome, greater Paris area. Emerg Infect Dis 12:990-993. (Pubitemid 43848425)
30. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphael JC, Gaillard JL, Gault E. 2009. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 48:48-56.
31. Souayah N, Nasar A, Suri MF, Qureshi AI. 2007. Guillain-Barré syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 25:5253-5255. (Pubitemid 46977531)
32. Svennerholm L. 1964. The gangliosides. J Lipid Res 5:145-155.
33. Taguchi K, Ren J, Utsunomiya I, Aoyagi H, Fujita N, Ariga T, Miyatake T, Yoshino H. 2004. Neurophysiological and immunohistochemical studies on Guillain-Barré syndrome with IgG anti-GalNAc-GD1a antibodies - effects on neuromuscular transmission. J Neurol Sci 225:91-98.
34. Usuki S, Sanchez J, Ariga T, Utsunomiya I, Taguchi K, Rivner MH, Yu RK. 2005. AIDP and CIDP having specific antibodies to the carbohydrate epitope (-NeuAca2-8NeuAca2-3Galb1-4Glc-) of gangliosides. J Neurol Sci 232:37-44. (Pubitemid 40585840)
35. Usuki S, Taguchi K, Cawthraw SA, Shibata K, Ariga T, Newell DG, Yu RK. 2006a. Human and chicken antibodies to gangliosides following infection by Campylobacter jejuni. Exp Neurol 200:50-55. (Pubitemid 44097019)
36. Usuki S, Thompson SA, Rivner MH, Taguchi K, Shibata K, Ariga T, Yu RK. 2006b. Molecular mimicry: sensitization of Lewis rats with Campylobacter jejuni lipopolysaccharides induces formation of antibody toward GD3 ganglioside. J Neurosci Res 83:274-284. (Pubitemid 43184391)
37. Usuki S, Pajaniappan M, Thompson SA, Yu RK. 2007. Chemical validation of molecular mimicry: interaction of cholera toxin with Campylobacter lipooligosaccharides. Glycoconj J 24:167-180. (Pubitemid 46352523)
38. Usuki S, Nakatani Y, Taguchi K, Fujita T, Tanabe S, Utsunomiya I, Gu Y, Cawthraw SA, Newell DG, Pajaniappan M, Thompson SA, Ariga T, Yu RK. 2008. Topology and patch-clamp analysis of the sodium channel in relationship to the anti-lipid A antibody in campylobacteriosis. J Neurosci Res 86:3359-3374.
39. van Doorn PA, Ruts L, Jacobs BC. 2008. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7:939-950.
40. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG. 1988. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 26:187-201.
41. Westphal O, Lüderitz O, Bister F. 1952. Über die Extaktion von Bakterien mit Phenol/Waser. Z Naturforsch 7b:148-155.
42. Willison HJ, Almemar A, Veitch J, Thrush D. 1994. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology 44:2395-2397. (Pubitemid 24984774)
43. Yu RK, Usuki S, Ariga T. 2006. Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Infect Immun 74:6517-6527. (Pubitemid 44913126)
44. Yuki N. 2007. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 35:691-711. (Pubitemid 46838749)
45. Yuki N, Tagawa Y. 1998. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 154:14-17. (Pubitemid 28123209)
46. Yuki N, Yoshino H, Sato S, Miyatake T. 1990. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40:1900-1902.
47. Yuki N, Koga M, Hirata K. 2000. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome? Acta Neurol Scand 102:132-134. (Pubitemid 30469509)
48. Zhang ZY, Zhang Z, Schluesener HJ. 2009. Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis. Neuroscience 159:136-142.